> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Sees No New Nuplazid Risks
- URL: https://www.fdaweb.com/fda-sees-no-new-nuplazid-risks/
- Published: 2018-09-20T12:00:00.000Z
- Updated: 2026-09-15T00:33:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142409

FDA says its review of all postmarketing reports of deaths and serious adverse events reported with use of Acadia Pharmaceuticals’ Parkinson’s drug Nuplazid (pimavanserin) did not identify any new or unexpected safety findings or findings that are inconsistent with the established safety profile described in the drug label. “After a thorough review,” an agency drug safety [update](https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm?utm%5Fcampaign=FDA%20analysis%20finds%20no%20new%20or%20unexpected%20safety%20risks%20associated%20with%20Nuplazid&utm%5Fmedium=email&utm%5Fsource=Eloqua) says, “FDA’s conclusion remains unchanged that the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Parkinson’s disease psychosis.”

The update says that although no new or unexpected safety risks were identified, some potentially concerning prescribing patterns were observed, such as the concomitant use of other antipsychotic drugs or drugs that can cause QT prolongation. The agency says prescribers should be aware of the risks described in the prescribing information.